The boom in specialty pharmaceuticals is reshaping the pharmacy industry's market structure as 10 companies account for 70 percent of specialty pharmacy revenues, according to Adam J. Fein, CEO of the Drug Channels Institute and author of the study on pharmacy economics and the pharmaceutical supply chain.

A British senior executive working in China for the global pharmaceutical giant GlaxoSmithKline helped orchestrate a long-running bribery and fraud scheme that involved making secret payments to doctors, hospital staff and government officials to bolster drug sales, Chinese authorities said.